|
Market Cap (5-Jun) $15,812,900 (1,318th) |
Close (30-Jun) $0.040 |
Volume (30-Jun) 2,106,389 |
Shortsold (23-Jan) 143,231 (0.01%) (538th) |
|
52w High $0.029 |
52w Low $0.010 |
P/E - |
EPS 0 |
NTI released this announcement to the ASX on 20 March 2023, 9:03. The announcement is marked as price sensitive, and is 3 page(s) in length and 199.04kb in size.
You can view all announcements from NTI and see how they appear on a price chart on the announcements page.
At the date of this announcement, NTI was 0.014% short sold according to ASIC data. It was ranked the 584th most shorted stock on the ASX. It is now ranked as the 538th most shorted stock on the ASX with 0.011% of total shares short sold as of the latest reported data (23 January 2026).
| Other Recent Announcements from NTI | |
|---|---|
| Notification of cessation of securities - NTI | 30 June 2023, 17:06 |
| Notification regarding unquoted securities - NTI | 28 June 2023, 16:14 |
| NTI to Present at Rett Syndrome Foundation Meeting | 5 June 2023, 8:27 |
| NTI to Launch Phase II Clinical Trial in Rett Syndrome | 20 March 2023, 9:03 |
| Investor Conference Call - 52 Week Autism Study Results | 17 March 2023, 10:01 |
| Investor Presentation | 17 March 2023, 9:53 |
| Phase I/II ASD Clinical Trials Results at 52 Weeks | 17 March 2023, 9:45 |
You must be logged in to post a reply.
Neurotech International 